Terns has a modest market cap of less than $800 million, and its possible upside could be massive.
These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond.
Telemedicine once seemed like it was going to revolutionize healthcare.
Terns Pharmaceuticals just proved that it's competitive in the weight loss field.
Innovative drugmakers developing treatments for conditions with high unmet needs can produce lucrative wins.
Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right track.
The company is looking especially good after some bad news coming from a rival.
An investment in these players today could score a big win down the road.
The biotech continued to get attention from both pundits and investors, thanks largely to its investigational obesity drug.
The S&P 500 Index ($SPX ) (SPY ) Wednesday closed up by +1.07%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up by +0.31%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up by +2.17%. Stocks...